Antitrust matters are rarely isolated within a single state or federal agency or jurisdiction. We represent clients facing multi-dimensional antitrust challenges on the transactional, regulatory and litigation fronts, mobilizing an unmatched combination of courtroom excellence, government experience and legal, economic and academic prowess on our clients’ behalf.
Paul, Weiss is advising Cigna Corporation on the regulatory clearance of the $6.3 billion sale of its group life and disability insurance business to New York Life.
Paul, Weiss won a major appeal in the Fifth Circuit on behalf of client Becton, Dickinson and Company (BD) in a long-running antitrust and false advertising litigation brought by competitor Retractable Technologies, Inc. (RTI).
Awards & Recognition
Corporate partner Scott Barshay and litigation partner Rick Rule have been named American Lawyer “Dealmakers of the Year.”
The year began with several notable developments. As we discussed in recent Client Memoranda, the Department of Justice (DOJ) and Federal Trade Commission (FTC) issued draft vertical merger guidelines, and the FTC announced new Hart-Scott-Rodino thresholds.
Cigna announced that the Antitrust Division of the DOJ cleared Cigna’s $67 billion acquisition of pharmacy benefits manager Express Scripts Holding.
In a victory for client Nomura and other defendant banks, Paul, Weiss and other joint defense firms won the dismissal of a consolidated class action alleging that Nomura and other major global financial institutions conspired to manipulate prices in the multitrillion-dollar global market for supranational, sub-sovereign and agency (SSA) bonds.
Paul, Weiss secured a significant antitrust appellate victory for global medical technology company Becton Dickinson & Company (BD).
Paul, Weiss is representing Elanco Animal Health Incorporated in its $7.6 billion cash-and-stock acquisition of the animal health business of Bayer AG, creating the world’s second-largest animal health business.